Theravance Biopharma

About Theravance Biopharma

Theravance Biopharma Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule medicines for serious diseases, with a primary emphasis on respiratory and neurologic conditions. Its portfolio includes YUPELRI, a once-daily nebulized therapy for chronic obstructive pulmonary disease (COPD), Ampreloxetine for neurogenic orthostatic hypotension, and TRELEGY for COPD and asthma. The company engages in collaborations and licensing agreements to advance its pipeline, aiming to address significant unmet patient needs through organ-selective medicines.